Oncolytics Biotech Inc T.ONC

And That's Not All

[Proboscises]

During the year end conference call a few other items were mentioned by Heineman and de Guttadauro besides stuff about breast and pancreatic cancer.

Tom Heineman: "Lastly, before handing off the call to Andrew, I would like to remind all listening that in addition to its pancreatic cancer cohort, GOBLET also includes cohorts evaluating pela atezolizumab combinations in metastatic colorectal and advanced anal cancer. We expect to have additional updates from these cohorts over the course of the year and have been pleased with the overall enrollment to date."

Andrew de Guttadauro: "One final note, we continue to advance our preclinical CAR-T program in ongoing discussions with multiple potential biopharma and research partners and maintain constructive conversations on a potential clinical trial."

In these conference calls time is limited and company participants tend to mention only those things they consider important.  In this case Heineman mentioned metastatic colorectal and anal cancer, and de Guttadauro mentioned CAR-T. As I discussed in earlier posts I believe we are getting hints that outcomes in the trials with Pela in colorectal and anal cancer, and the animal trial with Pela in combination withb CAR-T are looking good. 

Notice what was said in the year end Financial Results and Operational Highlights:

2023 Anticipated Milestones and Catalysts

• Overall response rate, progression-free survival, and evolving overall survival data from phase 2 BRACELET-1 metastatic breast cancer study: Q2 2023
• Preclinical data from the combination of pelareorep and CAR T therapy: Q2 2023
• Updated advanced/metastatic PDAC data from the GOBLET study: H2 2023
• Updates on the metastatic colorectal and advanced anal cohorts from the GOBLET study: H2 2023
• Guidance for the registration paths for HR+/HER2- metastatic breast cancer and advanced/metastatic PDAC: H2 2023